证券代码：002044 证券简称：美年健康 公告编号：2025-024 美年大健康产业控股股份有限公司 第八届监事会第三十次（临时）会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 监 事 会 美年大健康产业控股股份有限公司（以下简称"公司"）第八届监事会第三十 次（临时）会议于 2025 年 4 月 24 日以电子发送等形式发出会议通知，会议于 2025 年 4 月 29 日上午 11 时以通讯方式召开。应出席本次会议的监事 3 名，实 际出席会议的监事 3 名，会议由监事会主席夏庆仁先生主持。本次会议的召开符 合《中华人民共和国公司法》《公司章程》及有关法律、法规的规定。 二、监事会会议审议情况 1、审议并通过《公司 2025 年第一季度报告》 表决结果：赞成 3 票，反对 0 票，弃权 0 票。 经审核，监事会认为董事会编制和审核的《公司 2025 年第一季度报告》的 程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 《公司 202 ...

第九届董事会第九次（临时）会议决议公告 证券代码：002044 证券简称：美年健康 公告编号：2025-023 美年大健康产业控股股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 美年大健康产业控股股份有限公司（以下简称"公司"）第九届董事会第九次 （临时）会议于 2025 年 4 月 24 日以电子发送等形式发出会议通知，会议于 2025 年 4 月 29 日上午 10:30 以通讯方式召开。应出席本次会议的董事为 9 名，实际出 席会议的董事为 9 名。会议由公司董事长俞熔先生主持，公司监事及部分高级管 理人员列席了会议。本次会议的出席人数、召开表决程序、议事内容均符合《中华 人民共和国公司法》《公司章程》等有关规定。 二、董事会会议审议情况 1、审议并通过《公司 2025 年第一季度报告》 三、备查文件 1、公司第九届董事会第九次（临时）会议决议； 2、公司第九届董事会审计委员会第四次会议决议。 特此公告。 美年大健康产业控股股份有限公司 董 事 会 表决结果：赞成 9 票，反对 0 票，弃权 0 票。 公司董事会审计 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-026 美年大健康产业控股股份有限公司 关于 2023 年股票期权激励计划首次授予的 部分股票期权注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"）于 2025 年 4 月 15 日 召开第九届董事会第八次会议、第八届监事会第二十九次会议，审议通过《关于 2023 年股票期权激励计划首次授予的股票期权第一个行权期行权条件未成就及 注销部分股票期权的议案》。鉴于公司 2023 年股票期权激励计划首次授予的股 票期权第一个行权期行权条件未成就，以及公司 19 名首次授予股票期权的激励 对象已离职，不再具备激励对象资格，根据《公司 2023 年股票期权激励计划（草 案修订稿）》相关规定，同意公司对 2023 年股票期权激励计划合计 22,039,750 份股票期权进行注销。具体内容详见公司于 2025 年 4 月 17 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于 2023 年股票期权激励计划首次授予的股票 期权第一个 ...

美年健康（002044）公告，2025年第一季度营收为17.54亿元，同比下降2.62%；净亏损2.75亿元，去年 同期净亏损2.87亿元。 ...

Financial Performance - The company's revenue for Q1 2025 was ¥1,754,077,010.26, a decrease of 2.62% compared to ¥1,801,337,075.22 in the same period last year[3] - The net profit attributable to shareholders was a loss of ¥275,338,119.16, an improvement of 3.94% from a loss of ¥286,618,131.63 in the previous year[3] - The net cash flow from operating activities improved by 14.87%, amounting to -¥462,697,643.96 compared to -¥543,488,624.74 in the previous year[3] - Total operating revenue for the current period is ¥1,754,077,010.26, a decrease of 2.6% from ¥1,801,337,075.22 in the previous period[42] - Net profit for the current period is a loss of ¥297,617,884.18, compared to a loss of ¥309,314,500.19 in the previous period, showing an improvement[43] Assets and Liabilities - Total assets decreased by 4.51% to ¥19,218,156,364.19 from ¥20,126,714,816.93 at the end of the previous year[3] - The company's total equity is now ¥8,391,237,817.39, down from ¥8,702,926,051.84 in the previous period[40] - Total liabilities decreased to ¥10,826,918,546.80 from ¥11,423,788,765.09 in the previous period[40] - The total long-term equity investments as of March 31, 2025, were CNY 945,800,550.87, slightly down from CNY 950,719,098.06[38] Cash Flow - Cash flow from operating activities is ¥1,814,053,421.66, compared to ¥1,867,527,795.44 in the previous period[46] - The net cash flow from operating activities was -462,697,643.96, an improvement from -543,488,624.74 in the previous period, indicating a reduction in cash outflow[47] - The net cash flow from financing activities was -193,815,346.43, worsening from -143,331,365.73, showing increased cash outflow for debt repayment and other financing activities[48] - The net cash flow from investing activities was -132,544,834.58, worsening from -68,006,011.17, indicating challenges in investment returns[47] Shareholder Information - Shareholders' equity attributable to the parent company decreased by 3.61% to ¥7,626,025,050.06 from ¥7,911,964,163.35 at the end of the previous year[3] - The total number of ordinary shareholders at the end of the reporting period was 189,346[10] Operational Highlights - In 2025, the company aims for "comprehensive efficiency improvement and leapfrog growth," focusing on refined management of medical quality and service, with a target revenue of RMB 175.41 million, a decrease of 2.62% year-on-year[14] - Revenue generated from AI technology reached RMB 5.42 million, an increase of 71.76% compared to the previous year, driven by services such as cardiopulmonary screening and AI-MDT reports[14] - As of March 31, 2025, the company operates 574 branches, with 310 being controlled branches[14] - The company established its first weight management center, implementing a "three-expert management" model to provide comprehensive weight management services[16] Community and Social Responsibility - The company is actively involved in social responsibility initiatives, including providing free health check-ups for visually impaired individuals[20] - The company launched a public health initiative targeting "working mothers," providing customized health check-ups and consultations to 1,000 participants across 10 events in 8 cities[28] - The company reported a significant focus on mental health initiatives for students, engaging over 200 participants in a health awareness event[23] - The company is actively involved in community health education, combining professional medical knowledge with public service to enhance community health awareness[34] Cost Management - The company experienced a 50.71% increase in taxes and surcharges, totaling ¥1,577,678.94 compared to ¥1,046,807.78 in the previous year[8] - Cash outflow for purchasing goods and services was 636,478,623.02, down from 785,897,556.52, indicating cost control measures[47] - The company paid 1,299,640,038.19 in employee compensation, slightly up from 1,271,097,876.36, reflecting stable workforce costs[47]

Core Insights - The health checkup industry in China is experiencing a recovery driven by the aging population and increasing demand for chronic disease management, with a projected market size exceeding 520 billion yuan by 2030 [1] - The company is leveraging a "transfer and control" model to efficiently integrate regional resources, enhancing its competitive advantage amid rising industry concentration [1] - The company is focusing on the aging market by strategically developing essential projects such as brain health, cardiovascular early screening, and tumor marker testing, creating a comprehensive service system from prevention to health management and medical referral [1] Industry Growth - The industry has seen a compound annual growth rate (CAGR) of 15.06% from 2012 to 2022, indicating robust growth potential [1] - The company aims to complete 25.12 million health check services in 2024, with an 8.25% year-on-year increase in average revenue per service to 672 yuan [1] Business Strategy - The company is implementing a multi-channel marketing strategy to optimize customer structure, focusing on both online and offline channels [2] - The individual checkup revenue share is expected to rise from 17% in 2021 to 24.1% in 2024, reflecting a shift towards personalized services [2] - The company is building a large structured health database with over 1 billion imaging data points and 200 million structured health data points, creating a "data-algorithm-product" closed loop [2] Technological Advancement - The company has upgraded its strategy to focus on AI, developing systems for intelligent appointment scheduling, AI-assisted diagnosis, and post-checkup health interventions [3] - AI products for early disease screening have significantly improved accuracy in brain health assessments and lung nodule identification [3] - The company is transitioning from a health check service provider to a health management solution platform, with AI-related revenue projected to exceed 215 million yuan in 2024 [3] Financial Projections - The company is expected to benefit from the "Healthy China" strategy and the silver economy, with projected revenues of 12.14 billion yuan in 2025, 14.02 billion yuan in 2026, and 16.32 billion yuan in 2027, reflecting year-on-year growth rates of 13.46%, 15.46%, and 16.41% respectively [4] - Net profit attributable to the parent company is projected to reach 605 million yuan in 2025, 1.01 billion yuan in 2026, and 1.27 billion yuan in 2027, with significant growth rates of 114.47%, 66.80%, and 25.63% respectively [4]

证券代码：002044 证券简称：美年健康 公告编号：2025-022 美年大健康产业控股股份有限公司 关于公司及下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于 2024 年 12 月 13 日召开的第九届董事会第五次（临时）会议及 2024 年 12 月 30 日召开 的 2024 年第六次临时股东大会，审议通过了《关于公司及下属子公司申请融资额 度并提供担保的议案》，同意公司及部分下属子公司 2025 年度为公司及合并报表 范围内的子公司提供担保额度累计不超过人民币 49 亿元。具体内容详见公司于 2024 年 12 月 14 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于公司及下属 子公司申请融资额度并提供担保的公告》（公告编号：2024-111）。 二、进展情况 近日，公司与上海银行股份有限公司浦东分行（以下简称"上海银行"）签署了 《最高额保证合同》，为美年大健康产业（集团）有限公司（以下简称"美年大健 康"）提供主债 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，美年健康披露了2024年年报。年报数据显示，报告期内公司实现营收107.02亿元，同比微降 1.76%；归母净利润为2.82亿元，同比下降44.18%；扣非净利润2.52亿元，同比下降45.52%。 结合往期业绩表现看，公司2023年业绩短暂回暖后再度出现回落迹象，颇具信号意义。回顾历史，2019 年至今，美年健康的业绩表现有如过山车，业绩大起大落的背后与公司商誉减值、疫情扰动等密不可 分。而2024年公司并未进行大额商誉减值计提，疫情也早已成为过去时。在此背景下，公司盈利规模仍 未得到显著修复。 在连锁体检机构赛道中，由于体检设备、体检服务、体检服务等明显趋同，难以拉开大的差距，那么门 店的数量以及覆盖城市则成为衡量体检中心在行业中地位的重要指标。为了满足扩张的需求，美年健康 自2011年起便开启了激进并购的模式。 美年健康的发展模式转为体系内孵化，即上市公司先少量参股，一般参股份额在10%左右，余下的股份 则由其成立但在体系之外的并购基金或其他投资人持有。而在培育期中，随着标的体检中心营运逐渐走 上正轨，具备盈利能力，美年健康 ...

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].